Ono, Kyowa Kirin, BMS to Conduct PI Study of Opdivo and Poteligeo as Combination Therapy in Patients with Solid Tumors

Ono Pharmaceutical, Kyowa Hakko Kirin, and Bristol-Myers Squibb (BMS) of the US announced on December 10 that they entered into a collaborative development agreement on December 8 in the field of immuno-oncology. Under the agreement, a domestic PI clinical trial...read more